ClinConnect ClinConnect Logo
Search / Trial NCT05967390

Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE)

Launched by CHINESE UNIVERSITY OF HONG KONG · Jul 28, 2023

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

Aging Scalp To Cortex Distance Transcranial Brain Stimulation Parkinson Disease Simulation Predictor

ClinConnect Summary

Objective: This study aimed to investigate the region-specific SCD and its relationship with morphometric features and cognitive function in age- and disease-specific populations. Methods: The SCD and cortical thickness (CT) of left primary motor cortex (M1) and dorsolateral prefrontal cortex (DLPFC) were measured in cognitively normal adults and dementia patients. CT-adjusted SCD was used to control the influence of CT on SCD. Head model was developed to simulate the impact of SCD on the electric field induced by transcranial electrical stimulation.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Right-handed as assessed by the Edinburgh Inventory
  • Able to attend TMS interventions
  • Consent
  • Independent in daily life activities
  • Exclusion Criteria:
  • Uncorrected visual or auditive deficits not allowing the realization of the test
  • Evolutive disease (such as cancer)
  • Neurological or psychiatric antecedent
  • Counter-indication to MRI

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Trial Officials

Hanna LU, PhD

Principal Investigator

Chinese University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported